T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells

被引:60
作者
Raitakari, M
Brown, RD
Sze, D
Yuen, E
Barrow, L
Nelson, M
Pope, B
Esdale, W
Gibson, J
Joshua, DE
机构
[1] Turku Univ, Cent Hosp, Dept Clin Chem, Turku 20520, Finland
[2] Royal Prince Alfred Hosp, Inst Haematol, Sydney, NSW, Australia
关键词
myeloma; T cell; immunophenotype; TCR; monoclonal antibody;
D O I
10.1046/j.1365-2141.2000.02131.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The presence of T-cell clones in peripheral blood has been previously shown to be associated with a survival advantage in patients with multiple myeloma and suggests that the expanded T-cell populations may be involved in an anti-tumour response. We studied the T-cell receptor (TCR) repertoire of 38 patients with myeloma to identify and characterize the expanded T-cell populations by now cytometry. T-cell expansions were found in 79% of the patients. The expansions occurred randomly among the 21 variable regions of the TCR beta chain (V beta) studied, representing 62% of the V-beta repertoire, and were stable during an 18-month follow-up. The phenotype of the expanded V-beta populations was predominantly CD8(+), UD57(+), CD28(-) and perforin(+), which differed significantly from the other nonexpanded V beta populations. The expression of the apoptosis markers Fas (CD95) and bcl-2 were similar between the expanded and non-expanded V beta populations. In conclusion, expanded T-cell populations were frequent in patients with myeloma, they remained unchanged during follow-up and had phenotypic characteristics of cytotoxic T cells. These data add further support to the concept that the T-cell expansions may have an immunoregulatory role in myeloma.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [41] Single-cell transcriptomics uncovers an instructive T-cell receptor role in adult γδ T-cell lineage commitment
    Scaramuzzino, Sara
    Potier, Delphine
    Ordioni, Robin
    Grenot, Pierre
    Payet-Bornet, Dominique
    Luche, Herve
    Malissen, Bernard
    EMBO JOURNAL, 2022, 41 (05)
  • [42] Clinical Insignficance of Monoclonal T-Cell Populations and Duodenal Intraepithelial T-Cell Phenotypes in Celiac and Nonceliac Patients
    Celli, Romulo
    Hui, Pei
    Triscott, Hannah
    Bogardus, Sidney
    Gibson, Joanna
    Hwang, Michael
    Robert, Marie E.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (02) : 151 - 160
  • [43] Hepatosplenic γδ T-cell Lymphoma: An Overview
    Visnyei, Koppany
    Grossbard, Michael L.
    Shapira, Ilan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04) : 360 - 369
  • [44] T-cell virtuosity in ''knowing thyself"
    Acuto, Oreste
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [45] Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma -: evaluation of T-cell responses by different read-out systems
    Abdalla, Amir Osman
    Hansson, Lotta
    Eriksson, Ingrid
    Nasman-Glaser, Barbro
    Rossmann, Eva D.
    Rabbani, Hodjattallah
    Mellstedt, Hakan
    Osterborg, Anders
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 110 - 114
  • [46] TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
    Gazitt, Y
    LEUKEMIA, 1999, 13 (11) : 1817 - 1824
  • [47] THE ONCOPROTEIN PHENOTYPE OF PLASMA-CELLS FROM PATIENTS WITH MULTIPLE-MYELOMA
    BROWN, RD
    POPE, B
    LUO, XF
    GIBSON, J
    JOSHUA, D
    LEUKEMIA & LYMPHOMA, 1994, 16 (1-2) : 147 - 156
  • [48] TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
    Y Gazitt
    Leukemia, 1999, 13 : 1817 - 1824
  • [49] Current Status of CAR-T Cell Therapy in Multiple Myeloma
    Reguera-Ortega, Juan Luis
    Garcia-Guerrero, Estefania
    Perez-Simon, Jose Antonio
    HEMATO, 2021, 2 (04): : 660 - 671
  • [50] A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs)
    Stone, Jennifer D.
    Aggen, David H.
    Schietinger, Andrea
    Schreiber, Hans
    Kranz, David M.
    ONCOIMMUNOLOGY, 2012, 1 (06): : 863 - 873